<DOC>
	<DOCNO>NCT00973986</DOCNO>
	<brief_summary>The aim study investigate effect CYP3A polymorphisms pharmacokinetics Atorvastatin Chinese subject coronary heart disease .</brief_summary>
	<brief_title>Effect CYP3A Genetic Polymorphisms Pharmacokinetics Atorvastatin</brief_title>
	<detailed_description>Large variability exist individual response statin . CYP3A polymorphisms likely contribute variable response drug primarily metabolize CYP3A include atorvastatin .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Subjects must demonstrate willingness participate study comply procedure sign write informed consent . Subjects must &gt; =35 year &lt; =70 year age . Subjects must LDLC concentration &gt; =2.6 mmol/L TC concentration &gt; =4.14 mmol/L Body mass index ( BMI ) must within range 19 30 patient . Subjects must document coronary heart disease one follow feature : Documented stable angina ( evidence ischemia exercise test ) History myocardial infarction History percutaneous coronary intervention ( without stent placement ) Documented history unstable angina nonQ wave myocardial infarction . Diabetes endocrine metabolic disease . Congestive heart failure define New York Heart Association ( NYHA ) Class III IV . Uncontrolled cardiac arrhythmia . Uncontrolled hypertension ( Systolic BP &gt; 160 mm Hg and/or Diastolic BP &gt; 100 mmHg two consecutive measurement ) . Liver kidney disease confirm abnormal lab value function . Smokers report cigarette use 10 cigarette per day . Subjects consume &gt; 2 alcoholic drink day . ( A drink : beer , glass wine , single measure spirit ) . Known human immunodeficiency virus ( HIV ) positive . Cancer . Subjects follow concomitant medication : Medications potent inhibitor CYP3A , include cyclosporine , itraconazole , fluconazole , ketoconazole , erythromycin clarithromycin , nefazodone , protease inhibitor , mibefradil large amount grapefruit juice ( &gt; 1 quart/day ) . Lipidlowering agent : niacin ( &gt; 200 mg/day ) take within 5 week , fibric acid derivative take within 8 week .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>atorvastatin</keyword>
	<keyword>genetic polymorphism</keyword>
	<keyword>coronary heart disease</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>CYP3A</keyword>
</DOC>